Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results (scientific article published in January 2009)

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure

Q46626273

Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples

Q46970626

Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker

Q48358493

Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction.

Q50957875

Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

Q52429603

Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.

Q54518104

Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)

Q57628866

Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study

Q58816577

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Q28372091

Prediction of creatinine clearance from serum creatinine

Q29615603

Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction.

Q31795978

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling

Q33862454

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

Q34187441

Guidelines for the diagnosis and treatment of chronic heart failure

Q34516865

Pathophysiologic and therapeutic importance of tissue ACE: a consensus report

Q34714408

The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening

Q35142309

Serial echocardiographic assessment of left ventricular mass: how blinded should readers be?

Q35862964

Left atrial size: physiologic determinants and clinical applications

Q36509741

Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death

Q36847159

The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure

Q38364177

Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms

Q38776803

The interplay between haemodynamic load, brain natriuretic peptide and left atrial size in the early stages of essential hypertension

Q40334421

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

Q40548139

Aldosterone escape during ACE inhibitor therapy in chronic heart failure

Q41016806

Perceived benefit after participating in positive or negative/neutral heart failure trials: the patients' perspective.

Q43540807

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

Q43573505

Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure

Q44054779

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

Q44205751

Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure

Q44472822

P433

issue

P921

main subject

heart failure

Q181754

chronic heart failure

Q11829287

P304

page(s)

68-76

P577

publication date

2009-01-01

P1433

published in

European Journal of Heart Failure

Q5017954

P1476

title

Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results

P478

volume

Reverse relations

cites work (P2860)

Q36792952	Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis
Q40362633	Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new.
Q37897992	Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
Q48882910	Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
Q37821172	Aldosterone antagonists in heart failure
Q38120241	Aldosterone receptor antagonists: current perspectives and therapies
Q33688485	Aldosterone receptor antagonists: effective but often forgotten
Q83131285	Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF
Q90625413	Are patients in heart failure trials representative of primary care populations? A systematic review
Q28080002	Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer
Q57689089	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction
Q37574673	Blocking aldosterone in heart failure
Q37911729	CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure.
Q44825076	Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT.
Q42851021	Clinical trials update from the European Society of Cardiology Meeting 2010: SHIFT, PEARL‐HF, STAR‐heart, and HEBE‐III
Q58919610	Effects of antihypertensive treatment on endothelial function in postmenopausal hypertensive women. A significant role for aldosterone inhibition
Q41875563	Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials
Q92721760	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGi
Q85342202	Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms
Q38036328	Eplerenone for the treatment of cardiovascular disorders
Q44272913	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
Q26764927	Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Q48119758	Left ventricular reverse remodeling in dilated cardiomyopathy- maintained subclinical myocardial systolic and diastolic dysfunction.
Q38005732	Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances
Q49954326	Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives
Q36208986	Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
Q47783590	NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism.
Q38658657	Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
Q82601514	Potassium sparing diuretics as adjunct to mannitol therapy in neurocritical care patients with cerebral edema: effects on potassium homeostasis and cardiac arrhythmias
Q48529037	Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy
Q43101047	Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).
Q37503831	Should aldosterone blockade be used beyond current indications in heart failure?
Q37951665	Targeting the aldosterone pathway in cardiovascular disease.
Q30239022	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis
Q57118740	Timing of Left Ventricular Remodeling in Nonischemic Dilated Cardiomyopathy
Q38067485	When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?

P356	DOI	10.1093/EURJHF/HFN015
P8608	Fatcat ID	release_i7xtz6m2nbe3ln2y4tlc3pdyfa
P698	PubMed publication ID	19147459
P5875	ResearchGate publication ID	23791409